Democracy & Government

The Reason Why Booker and the Big Pharma Dems Have No Excuse

Democrats like this are the reason Democrats keep losing.

The Reason Why Booker and the Big Pharma Dems Have No Excuse

Sen. Cory Booker (D-NJ) listens during a Senate Foreign Relations Committee confirmation hearing for Rex Tillerson, former chief executive officer of Exxon Mobil Corp. and secretary of state nominee for President-elect Donald Trump on Wednesday, Jan. 11, 2017. (Photo by Andrew Harrer/Bloomberg via Getty Images)

This post originally appeared at OurFuture.org.

It’s devastating, and potentially lethal, when Americans can’t afford life-saving drugs because their elected representatives are in thrall to Big Pharma. It’s disappointing when Democrats offer implausible excuses for their votes, as Sen. Cory Booker and 12 other senators did last week.

But here’s the big question: If Booker and the other Democrats are so concerned about drug safety, why did they vote for the 21st Century Cures Act?

And it’s downright outrageous when those same Democrats claim their votes were driven by drug-safety concerns, since all 13 voted to lower drug safety standards when they supported the 21st Century Cures Act.

If Booker and the others hadn’t broken with their party and ignored the needs of the American people, a budget amendment from Sens. Bernie Sanders and Amy Klobuchar would have paved the way for the importation of prescription drugs from Canada, where they cost far less than they do in the United States.

This was a rare opportunity for bipartisan progress. Twelve Republicans broke with their party to support the amendment. If these Democrats hadn’t moved the other way, it would have passed. Their betrayal crushed one of the few remaining rays of hope for the millions of Americans whose health and financial security are endangered by the new Republican Congress.

Booker attempted to defend his vote in a statement to Jezebel’s Ellie Schechet, in which he said:

Any plan to allow the importation of prescription medications should also include consumer protections that ensure foreign drugs meet American safety standards. I opposed an amendment put forward last night that didn’t meet this test.

Nonsense. Canadian testing is as strong as its American equivalent, and most Canadian drugs are manufactured in the same locations as their US counterparts. And note the use of the word “foreign.” It seems designed to trigger xenophobic fears, and to hide the fact that drugs would only have been imported from one country: Canada.

What’s more, the Sanders/Klobuchar amendment was only a first step, so there was plenty of time to address any lingering concerns. Sen. Klobuchar has already co-sponsored a bill with Sen. John McCain called the “Safe and Affordable Drugs From Canada Act” that specifies how the process could work safely and efficiently.

But here’s the big question: If Booker and the other Democrats are so concerned about drug safety, why did they vote for the 21st Century Cures Act? Sold as a path to innovation, the bill was actually a massive giveaway to drug companies that wanted an end-run around safety regulations. It came with promises to spend more on public health needs, but those promises were designed to be easily broken.

As Public Citizen noted, the bill’s passage “comes at the expense of patient safety by undermining requirements for ensuring safe and effective medications and medical devices.”

Democrats should ask themselves: Is this the kind of leader they need to recover from devastating losses up and down the ticket?

Every vote in favor of the 21st Century Cures Act was misguided. But it takes a special kind of hypocrisy to vote for a measure that demonstrably lowers safety standards, and then cite safety as a reason for voting against the Sanders/Klobuchar amendment, which doesn’t. There’s only one way to explain these seemingly inconsistent votes: They both benefit Big Pharma.

Schechet reports that, perhaps not coincidentally, the Democrats who voted against the Sanders/Klobuchar amendment included some of biggest recipients of pharma cash on their side of the aisle. Booker tops that list with $267,338. Sen. Patty Murray was close behind with $254,649, while Robert Casey received $250,730 and Michael Bennet netted $222,000.

Booker deserves special attention, since he appears to be positioning himself for a 2020 presidential run. Booker received nearly $2 million from Wall Street for his 2014 Senate race. The financial industry also heavily backed his Newark mayoral campaign, and he has received large sums from law firms and real estate. When Barack Obama took a rhetorical jab against opponent Mitt Romney’s investment firm, Booker rabbit-punched him from the right by calling his remarks “nauseating.”

“Stop attacking private equity,” Booker added.

Democrats should ask themselves: Is this the kind of leader they need to recover from devastating losses up and down the ticket?

It is especially bitter to note that this vote came the week before the nation’s celebration of Dr. Martin Luther King Jr. “Of all the forms of inequality,” Dr. King once said, “injustice in health is the most shocking and inhuman.”

While their motives cannot be known with any certainty, the votes of these 13 Democrats inevitably raises the problems of legalized corruption that underpin our play-for-pay political system. One thing is already clear: Democrats like this are the reason Democrats keep losing.

As Sanders wrote in 2015, “Americans pay the highest prices for prescription drugs in the world — by far.”

These 13 Democrats have damaged efforts to provide truly affordable health care. They’ve robbed their party of the moral high ground on an issue voters care deeply about. And they’ve ceded the rhetorical high ground to the empty posturing of the soon-to-be-inaugurated Bloviator in Chief, who said this week that drug companies are “getting away with murder.”

Democrats will have to move fast to undo the damage these senators have done.

Richard Eskow

Richard (RJ) Eskow is a writer, a former Wall Street executive and a radio journalist. He has experience in health insurance and economics, occupational health, risk management, finance and IT. Follow him on Twitter: @rjeskow.

SHARE THIS ARTICLE

RELATED CONTENT